晚期非透明细胞肾细胞癌的一线治疗:系统综述与荟萃分析
该系统综述与荟萃分析检索了截至2024年12月31日的PubMed、Embase和Cochrane Library数据库,纳入23项研究,评估免疫检查点抑制剂(ICI)为基础的一线方案治疗转移性非透明细胞肾细胞癌(nccRCC)的疗效,汇总客观缓解率26.6%、疾病控制率57.8%、中位无进展生存期6.59个月、中位总生存期21.11个月,结论认为ICI尤其是联合靶向治疗显示出有前景的疗效。
要点
- 汇总客观缓解率为26.6%,疾病控制率为57.8%。
- 中位无进展生存期为6.59个月,中位总生存期为21.11个月。
- ICI单药有效,联合靶向治疗临床结局更优。
核心结论
- 该系统综述与荟萃分析发现,ICI尤其是联合靶向治疗在转移性nccRCC中显示出有前景的疗效。
- 这些发现支持将其纳入治疗指南,并强调个体化治疗策略的重要性。
- 未来研究应关注长期结局、安全性特征及生物标志物识别以优化患者选择并改善结局。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase和Cochrane Library数据库自建库至2024年12月31日的文献。
- 纳入23项研究,涵盖nccRCC各亚型,报告以ICI为基础的治疗及ORR、PFS、OS、DCR数据。
- 由两名独立评价者提取数据,分歧由第三位专家解决;观察性研究质量采用纽卡斯尔-渥太华量表评估。
- 采用随机效应荟萃分析,异质性用I²统计量评估。
主要发现
- nccRCC治疗的汇总客观缓解率为26.6%,疾病控制率为57.8%。
- 中位无进展生存期为6.59个月,中位总生存期为21.11个月。
- ICI在nccRCC中显示出显著疗效,在不同亚型中均表现出明显的临床活性。
- ICI单药治疗显示出有效性,但联合治疗产生更优的临床结局。
关键数值与推荐
- 纳入标准为涉及nccRCC患者、报告以ICI为基础的治疗、并提供ORR、PFS、OS和DCR数据的研究。
- 主要结局指标为ORR、PFS、OS和DCR。
临床怎么用
- 原文结论认为这些发现支持将ICI尤其是联合靶向治疗纳入治疗指南,并强调个体化治疗策略的重要性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Non-clear cell renal cell carcinomas (nccRCCs) present considerable challenges owing to their heterogeneity and limited clinical trial representation. Understanding the benefits of combining immunotherapy and targeted therapy for these subtypes is crucial for improving patient outcomes. OBJECTIVE: To evaluate the efficacy of various first-line immunotherapy combinations and targeted therapy in treating metastatic nccRCC. DATA SOURCES: A systematic literature search was conducted across PubMed, Embase, and Cochrane Library databases from inception until December 31, 2024, using relevant keywords and medical subject headings terms. STUDY SELECTION: Studies were included if they involved patients with nccRCC, reported on immune checkpoint inhibitor (ICI)-based therapies, and provided data on objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and disease control rate (DCR). DATA EXTRACTION AND SYNTHESIS: Two independent reviewers extracted data, with discrepancies resolved by a third expert. Observational study quality was assessed using the Newcastle-Ottawa Scale. A random-effects meta-analysis was performed, and heterogeneity was evaluated using the I2 statistic. MAIN OUTCOME AND MEASURES: The primary outcomes of interest were ORR, PFS, OS, and DCR. RESULTS: The analysis included 23 studies encompassing various subtypes of nccRCC. Pooled results indicated an ORR of 26.6% and a DCR of 57.8% for nccRCC treatments. Median PFS was 6.59 months, and the median OS was 21.11 months. ICIs demonstrated significant efficacy in nccRCC, exhibiting marked clinical activity across different subtypes. Although monotherapy with ICIs showed effectiveness, combination therapies yielded superior clinical outcomes. CONCLUSIONS AND RELEVANCE: This systematic review and meta-analysis found that ICIs, particularly when combined with targeted therapies, showed promising efficacy in treating metastatic nccRCC. These findings support their integration into treatment guidelines and emphasize the importance of personalized treatment strategies. Future research should focus on long-term outcomes, safety profiles, and the identification of biomarkers to optimize patient selection and improve outcomes.
引用
- Petrelli F, Verri E, Ghidini A, et al. First-Line Therapy For Advanced Non-Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. JAMA Oncol. 2025. PMID: 40608318. doi:10.1001/jamaoncol.2025.1891
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。